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FOREWORD
The Biological and Clinical Relevance ofthe Somatostatin Receptor
The initial discovery of somatostatin was widely hailed as a significant advance in
physiology and biology. Few, however, envisaged the impact that this peptide would have
on the clinical arena. After a spate ofreports documenting its localization, physiological,
and pharmacological actions, attention turned to the regulation ofintracellular events and
the receptors which mediated its effects. Suffice it to say that within a decade a series of
long-acting analogs had been synthesized, and focus had been directed to clinical appli-
cations. The inhibition ofcell secretion, particularly in the gut, led to important consider-
ations in the management ofneuroendocrine secretory tumors. Further elaboration of the
family of receptor subtypes led to the consideration of differential regulation of not only
secretion but also cell growth. The concept ofradiosotopically labeling the molecule and
using its uptake on tumor receptors provided a unique clinical tool for the localization of
neoplasia-expressing somatostatin receptors. The subsequent amplification ofthis concept
to utilize an isotope capable ofdelivering therapeutic doses ofradiation to such lesions has
engendered considerable clinical interest and may well have substantial therapeutic bene-
fit. Further developments including the formulation of longer-acting analogs and the
recognition that their inhibitory actions may apply not only to secretory events but also to
proliferative events has aroused both considerable scientific and clinical interest.
This meeting could not have been held without the generous support ofMallinckrodt
Pharmaceuticals and the Yale University School of Medicine. It gathered many experts
from numerous countries whose fields ranged from the cellular and molecular domain to
the clinical areas of diagnostic and therapeutic strategies. It facilitated conside-ration of
the basic molecular mechanisms of somatostatin and its receptor activation in the context
of the clinical applications in diverse disease processes. Of particular interest were the
broad discussions relating clinical efficacy not only in terms ofsymptom management but
to tumor diagnosis and therapy. A broad consensus was established which supported the
concept that specific receptor-targeted pharmacotherapy was abiological and clinical tool
of considerable relevance in the management of neoplastic disease. In this respect,
somatostatin was recognized as the primogenitor ofan important and novel class ofdiag-
nostic and therapeutic agents.
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